introduction acute myeloid leukemia aml hematological malignancy currently effective treatment type aml mainly relies chemotherapy however prognosis many aml patient remains poor according cell morphology histochemical characteristic aml divided different type based cell morphology histochemical characteristic use immunology cytogenetics technology in-depth knowledge biological parameter aml cell provided basis accurate classification clinical outcome treatment aml time genomics widely used diagnosis treatment selection prognostic evaluation aml even accurate efficient prognostic prediction model biomarkers aml guide clinical diagnosis treatment yet developed therefore efficient objective biomarkers needed accurately evaluate diagnosis treatment prognosis aml small nuclear rna snrnas intracellular rna molecule ingredient rna spliceosome post-transcriptional processing eukaryote play role treatment mrna precursor abnormal variant snrnas widely perceived strongly linked malignant cancer including hepatocellular carcinoma hcc chronic lymphocytic leukemia cll sonic hedgehog medulloblastoma shh-mb melanoma many malignant tumor blood disease analyzing snrna data set tcga qin built prognostic risk scoring system based three snrnas predict prognosis patient gastrointestinal malignancy computational biology bioinformatics analysis method based similar method zhang constructed prognostic risk score system based eight m6a-associated snrnas predict prognosis hcc patient reviewing previous study found report value snrnas aml prognosis address research gap conducted integrated investigation clinical value molecular mechanism snrnas aml objective current study investigate snrnas associated aml prognosis using cancer genome atlas tcga whole transcriptome sequencing dataset result snrna risk score modeling survival analysis aml flow chart study shown fig aml patient record shown table french-american-british fab morphology type age notably associated overall survival patient aml tcga cohort multivariate cox proportional hazard regression model incorporated fab morphology type age model adjustment altogether snrnas obtained rna sequencing data tcga snrnas average value removed finally snrnas obtained edge r-normalization subsequent analysis using multivariate cox proportional hazard regression model platform screen prognostic snrnas identified snrnas notably associated aml fig table included prognostic snrnas platform optimal prognostic model screening finally obtained expression signature containing snrnas expression signature follows risk score exp rnu6-1274p 0.1409 exp rnu6-1143p 0.2353 exp rnu6-110p 0.2212 exp 0.1877 exp rnu4-8p 0.2214 exp rnu6-761p 0.3087 exp rnu6-1272p 0.5222 exp rnu6-202p 0.1926 exp rnu6-946p 0.2896 exp rnu6atac39p 0.3445 high- low-risk group divided according median value risk score observed high-risk aml patient notably shorter low-risk patient log-rank 0.0001 adjusted 0.0001 adjusted hazard ratio 5.524 confidence interval 3.180–9.598 fig subsequently survivalroc analysis showed risk score high accuracy predicting aml area roc curve auc predicting 5-years aml 0.907 fig multivariate survival analysis result ten prognostic snrnas presented table fig a–j also used nomogram model used predict individual prognosis snrna signature study observed snrna signature contributed death aml patient tcga cohort fig figure distribution map prognostic snrnas aml note figure drawn r4.0.2 version http full size image figure prognostic risk prediction expression signature aml composed ten prognostic snrnas distribution map expression signature patient survival time kaplan–meier curve aml patient different risk score survivalroc curve ten snrnas expression signature note figure drawn r4.0.2 version http full size image table multivariate survival analysis result ten snrnas included risk score model aml full size table figure kaplan–meier curve ten prognostic snrnas aml kaplan–meier curve rnu4-8p kaplan–meier curve rnu6-110p kaplan–meier curve rnu6-202p kaplan–meier curve rnu6-761p kaplan–meier curve rnu6-946p kaplan–meier curve rnu6-1143p kaplan–meier curve rnu6-1272p kaplan–meier curve rnu6-1274p kaplan–meier curve rnu6atac39p kaplan–meier curve note figure drawn r4.0.2 version http full size image figure nomogram ten prognostic snrnas expression signature aml risk score divided two group risk score grouped according score note figure drawn r4.0.2 version http full size image molecular mechanism exploration risk score aml well known snrna mainly involved post-transcriptional regulation pcg mrna function mainly regulating protein-coding gene pcg mrna expression therefore mrna regulated specific snrna exhibit co-expression interaction snrna expression level total pair interaction ten snrnas pcgs fig table identified co-expression analysis carried gene ontology kyoto encyclopedia gene genome kegg functional enrichment pcgs found pcgs significantly enriched dna repair nik nf-kappab-inducing kinase nuclear factor -kappa signaling planar cell polarity pathway regulation signal transduction p53 class mediator wnt signaling pathway cell receptor tcr signaling pathway cell division cell–cell adherens junction regulation mitotic cell cycle phase transition fanconi anemia pathway table result bingo enrichment analysis also verified result fig also performed survival analysis pcgs table screened pcgs associated aml fig table top three significant pcgs centromere protein cenpc adjusted 0.0001 adjusted 0.310 0.191–0.504 fig triggering receptor expressed myeloid cell treml2 adjusted 0.0001 adjusted 3.114 1.938–5.004 fig family sequence similarity member fam83g adjusted 0.0001 adjusted 3.015 1.880–4.837 fig figure interaction network plot ten prognostic snrnas co-expressed gene note figure drawn cytoscape 3.6.1 version http full size image figure survival analysis result co-expressed gene ten prognostic snrnas survival analysis result distribution map snrna co-expressed gene aml kaplan–meier curve centromere protein cenpc kaplan–meier curve triggering receptor expressed myeloid cell like treml2 kaplan–meier curve family sequence similarity member fam83g note figure drawn r4.0.2 version http full size image gene set enrichment analysis gsea result verified above-mentioned database annotation visualization integrated discovery v6.8 david v6.8 enrichment result pcgs gsea analysis using gene set found high-risk aml patient notably enriched following signaling pathway nf/kappa vegf toll-like receptor tlr pathway notch tumor protein tp53 apoptosis tcr akt1 mitogen-activated protein kinase mapk wnt tumor necrosis factor tnf aml cluster b-cell receptor bcr signaling pathway cytokine-cytokine pathway fig a–p table using gene set found aml patient high-risk phenotype notably enriched cell apoptotic process tnf pathway nf/kappa cell–cell adhesion mapk pathway tcr cell-mediated immunity cell activation involved immune response tlr signaling pathway fig a–p table figure gsea analysis result low- high-risk score phenotype aml using reference gene set note figure drawn gsea 2.2.3 version http full size image figure gsea analysis result low- high-risk score phenotype aml using reference gene set note figure drawn gsea 2.2.3 version http full size image also explored functional enrichment comparing differentially expressed gene degs patient high- low-risk aml edger screening degs two group obtained downregulated upregulated fig fig table enrichment analysis kegg revealed degs may involved following biological molecular mechanism positive regulation leukocyte chemotaxis cell junction transcriptional activator activity rna polymerase core promoter proximal region sequence-specific binding positive regulation transcription rna polymerase promoter ephrin receptor signaling pathway positive regulation cell proliferation cell–cell signaling focal adhesion ecm-receptor interaction pi3k-akt signaling pathway notch signaling pathway table bingo enrichment analysis also verified result fig prognostic analysis revealed degs significantly associated aml patient fig table s10 top three significant degs ac092042.3 adjusted 0.0001 adjusted 0.352 0.219–0.566 fig matrix metallopeptidase mmp7 adjusted 0.0001 adjusted 2.761 1.726–4.415 fig six homeobox six3 adjusted 0.0001 adjusted 0.374 0.234–0.598 fig degs imported online analysis tool connectivity map cmap screen potential small-molecule targeted therapy obtained six compound chicago sky blue clorsulon nefopam nicardipine streptomycin may targeted therapeutic drug risk score signature chemical structure shown fig a–f detailed list cmap result shown fig figure volcano map differentially expressed gene low- high-risk score phenotype note figure drawn r4.0.2 version http full size image figure survival analysis result differentially expressed gene degs low- high-risk score phenotype survival analysis result distribution map degs kaplan–meier curve aco92042.3 kaplan–meier curve matrix metallopeptidase mmp7 kaplan–meier curve six homeobox six3 note figure drawn r4.0.2 version http full size image figure cmap result degs low- high-risk score phenotype chemical formula chicago sky blue chemical formula chemical formula clorsulon chemical formula nefopam chemical formula nicardipine chemical formula streptomycin cmap result list full size image immune microenvironment immune infiltration analysis functional enrichment analysis risk score signature found risk score model markedly related immune-associated pathway mechanism tcr bcr signaling pathway end investigated signature two aspect immune microenvironment immune infiltration immunohistochemical analysis revealed significant difference stromal score two group fig 0.1716 nevertheless significant difference observed immune fig 0.0002 estimate score fig 0.0031 single-sample gene set enrichment analysis ssgsea revealed significant difference abundance ten immune cell immune infiltration low- high-risk aml abundance immune infiltrates higher high-risk aml patient low-risk patient fig figure comparison immune microenvironment score aml patient different risk score phenotype stromal score low- high-risk score phenotype immune score low- high-risk score phenotype estimate score low- high-risk score phenotype note figure drawn graphpad 6.01 version http full size image figure abundance immune infiltration aml patient different risk score phenotype compared ssgsea method note figure drawn r4.0.2 version http full size image discussion advent high-throughput sequencing technology greatly expanded understanding snrna dysregulation snrna closely associated cancer progression growing evidence snrna potential cancer diagnostic prognostic biomarker therapeutic target reviewing literature found report comprehensive exploration snrnas tumor including hematological malignancy review published multi-omics analysis based tcga dataset showed snrnas rarely reported searched snrna-related report included prognostic signature found reported cancer remaining nine snrnas new prognostic marker aml reported shuai showed mutation significantly associated poor outcome patient cll also suggested mutation strongly associated alcohol consumption hcc patient zhang extracted related snrna lung cancer patient first time proposed snrna might marker lung cancer subsequent study dong confirmed serf diagnostic marker lung cancer silencing overexpressing hela malignant tumor cell line found changing level notably affect migration invasion capability malignant tumor cell suzuki revealed mutation shh medulloblastoma notably suppress tumor suppressor gene patched ptch1 activate oncogene gli family zinc finger gli2 cyclin ccnd2 suggesting may serve therapeutic target tumor cheng upregulated pc-12 pheochromocytoma cell line sequenced overexpressed cancer cell line using whole-genome sequencing subsequently differentially expressed gene screened using bioinformatics analysis determine activation oncogene-related function pathway reviewing abovementioned literature found defined oncogene previous report current study discovered aml patient high expression poorer clinical outcome low expression consistent result previous study theoretical modeling gene/protein signaling network play important role understanding regulatory mechanism discovering potential therapeutic target disease verified regulatory mechanism caspase-1 gsdmd apoptosis pyrodeath using mathematical modeling combined quantitative western blot analysis team also used phase-field model explore protein phase separation controlled mrna computational model eventually confirmed experimentally therefore exploration biological mechanism use computer simulation model help understand functional mechanism discover potential therapeutic target disease computational biology deep learning predictive model include limited fivefold cross-validation experiment graph convolutional network graph attention network still difficult identify association genetic marker noncoding rna large-scale experiment computational biological method predict association gene noncoding rna remain potential effective way explore disease marker molecular mechanism however current prediction method still limitation need verified experiment field computational biology zhao also published variety program research strategy predicting association genetic marker noncoding rna well correlation single cell sequencing data computational biology study computational biology analysis method adopted similar current study also identified signaling pathway closely related aml bioinformatics enrichment analysis including tcr bcr wnt notch pathway t-cell receptor signaling pathway play important role cancer immunotherapy also used immunotherapy hematological malignancy tcr used pd-1 blockade therapy effect pd-1 blockade therapy aml patient determined different state cell t-cell receptor gene therapy significantly prevent aml recurrence bone marrow transplantation b-cell receptor widely used lymphatic malignancy targeted bcr signaling pathway used treatment cnl wnt signaling pathway shown closely related cancer study suggested deregulation wnt signaling beneficial malignant transformation tumor progression resistance conventional cancer therapy growing evidence dysregulated wnt signaling may also disrupt cancer immune surveillance thus promoting immune evasion resistance multiple immunotherapy including immune checkpoint blocker wnt signaling pathway involved regulating immune microenvironment leukemia wnt signaling may disrupted acute leukemia several way including change gene expression protein level epigenetic regulation mutation dysregulation wnt signaling pathway may different effect diagnosis progression aml also potential target aml treatment current study found risk score may play role aml regulating wnt signaling pathway also observed risk score significantly related immune microenvironment immune cell infiltration literature search found wnt signaling pathway play indispensable role aml dai explored prognostic value wnt gene family using tcga aml cohort found wnt family gene closely related clinical outcome aml multiple gene wnt signaling pathway also identified associated aml present study also identified another classic cancer-related signaling pathway notch signaling pathway notably associated risk score tumor immunity notch signaling pathway play indispensable role occurrence progression prognosis treatment hematological malignancy solid cancer serf target malignant tumor treatment although report found notch play oncogenic role solid tumor still controversial whether notch carcinogenic tumor suppressor aml kannan observed activated notch1 notch2 could inhibit growth aml cell vivo otherwise promote growth aml cell lobry observed similar result study whereas mutation notch1 often associated poor prognosis aml reviewing literature summarized potential molecular mechanism explored expression signature functional enrichment signaling pathway classic malignant tumor-related pathway also closely related tumor immunity current study also developed tumor immunity expression signature observed expression signature notably associated tumor immunity among screened drug chicago sky blue found associated aml cancer review previous study allosteric inhibitor macrophage migration mif inhibits osteoclast formation promotes osteogenesis inhibiting nf-kappa signaling pathway previous study nicardipine found enhance sensitivity tumor chemotherapy agent shi revealed nicardipine could enhance antitumor effect temozolomide glioblastoma multiforme gbm inhibiting stem cell autophagy promoting apoptosis nicardipine also reported significantly enhance inhibitory effect drug breast cancer cell proliferation chen used nicardipine interfere breast cancer cell line found nicardipine significantly inhibited migration colony-forming ability breast cancer cell exploring molecular mechanism found nicardipine achieves phenomenon regulating nrf2/ ho-1 axis matrix metalloproteinase-9 breast cancer cell nicardipine significantly inhibited growth prostate cancer xenograft nude mouse vivo review literature revealed remaining four drug associated cancer aml finding first reveal drug may targeted therapy aml however result need confirmed future study although found many interesting result study result still certain limitation small-sample study single cohort first single-cohort study lacked additional validation cohort second study mainly used bioinformatics analysis tool explore functional mechanism still need vivo vitro experimental verification however finding provide theoretical basis exploring potential clinical application snrnas aml lay foundation subsequent development snrna-related aml biomarkers conclusion current study preliminarily identified snrnas associated aml prognosis result revealed novel prognostic expression signature aml consisting ten prognostic snrnas conducted preliminary exploration potential biological function tumor immunity functional enrichment analysis revealed prognostic signature notably associated biological function pathway cell adhesion bcr tcr wnt notch signaling pathway also used cmap screen six potential targeted drug risk score aml chicago sky blue clorsulon nefopam nicardipine streptomycin immunological analysis revealed significant difference immune microenvironments aml patient high- low-risk phenotype immune infiltration abundance ten immune cell high-risk score phenotype significantly higher low-risk score phenotype however study single-center small-cohort study result require additional verification future study material method data preparation original rna sequencing rna-seq count dataset demographic information obtained tcga website http normalization raw sequencing data performed using edger platform excluded patient prognostic rna sequencing data patient included follow-up study patient inclusion exclusion criterion found previous study data used study met requirement tcga study approved ethic committee first affiliated hospital guangxi medical university approval number ky-e-325 snrna risk score modeling survival analysis aml multivariate cox proportional hazard regression model used screen snrnas related aml patient performed step function platform construct best risk-score model prognostic-related snrnas calculation formula follows risk score expsnrna βsnrna expsnrna βsnrna +···expsnrna βsnrna exp expression value nomogram model executed using rms package software efficacy risk score model predicting aml determined using survivalroc functional mechanism risk score aml evaluate potential functional mechanism snrnas risk score model explored three approach snrna-co-expressed gene gsea http degs extracted mrna expression profile matrix tcga rna-seq dataset evaluated co-expressed pcgs associated snrnas using pearson correlation coefficient subsequently david v6.8 http used screen pathway biological functional mechanism related snrna co-expression pcgs including gene ontology term kyoto encyclopedia gene genome kegg also used bingo app cytoscape v3.6.1 software http verify enrichment analysis result david also conducted functional enrichment analysis aml genome-wide dataset gsea v2.2.3 software using reference gene set including c2.all.v7.4 symbols.gmt c5.all.v7.4 symbols.gmt defined gsea result enrichment score 0.05 false discovery rate fdr 0.25 reaching statistical significance also used risk score group patient high- low-risk phenotype screened degs two phenotype using edger used degs functional enrichment explore mechanism degs defined fold change fdr value 0.05 also used deg screen potential aml risk score therapeutic small-molecule compound cmap http chemical structure obtained pubchem http immune microenvironment immune infiltration analysis used estimation stromal immune cell malignant tumor tissue using expression data estimate package score immune microenvironment platform calculated stromal score immune score estimate score bone marrow tissue aml patient used gene set variation analysis gsva package perform ssgsea platform evaluate abundance immune cell infiltration bone marrow tissue aml patient statistical analysis pearson correlation coefficient used evaluate co-expressed pcgs 0.05 considered co-expression interaction relationship kaplan–meier curve evaluated using log-rank test included demographic data related aml prognosis aml multivariate cox proportional hazard regression model adjustment platform adopts r4.0.2 version statistical analysis performed using spss version 22.0 difference considered statistically significant 0.05 ethic approval consent participate raw dataset aml included present study downloaded open access public database author involved animal human experiment according ethical guideline helsinki declaration study approved ethic committee first affiliated hospital guangxi medical university approval number ky-e-325